Subscribe
Share
Share
Embed
Five real advances in science, medicine, technology, and the environment, each verified against the original reporting. In this episode: A shigellosis vaccine candidate (WRSs2) showed 89% efficacy against Shigella sonnei in a trial published in; An international research team led by IPK Leibniz Institute published a high-quality reference genome; A new model simulates how solar panels can cool crops and reduce heat stress for workers in agrivoltaic; EMBL scientists discovered that phages use a single enzyme (T7 kinase) to shut down multiple bacterial; An injectable hydrogel platform allows drug-loaded nanocarriers to remain in joints for several weeks and.
Five Things Going Right is a daily five-minute podcast covering real, verifiable progress in science, medicine, technology, and the environment. Every weekday, hosts Grace and Josh walk through five stories that actually happened, each checked against the original reporting from sources like the WHO, the IEA, Nature, and university research. A calm, fact-grounded start to your day. New episodes every weekday morning.
Welcome, this is 5 things going right, the news that's actually good. 5 stories, 5 minutes, all of them true. Hi everyone, I'm Grace. Today is Thursday, August 20th, 2026. Let's start with some promising news in the world of vaccines. A trial published in the Lancet Infectious Diseases this summer reported that a vaccine candidate called W R S S 2 showed 89% efficacy against Shigelisani. This is one of the bacteria responsible for fatal diarrheal disease. That's right, Grace, Dr. Kausar Talat from the Johns Hopkins Bloomberg School of Public Health described this as the best efficacy the field has seen so far. It's worth noting that no Shigelosis vaccine has ever been licensed, despite over a century of attempts. However, the report doesn't specify the trial size, population, or follow-up period. So it's still unclear how this efficacy will translate to areas where Shigella deaths are most prevalent. Genetics, an international research team led by the IPK-Leibniz Institute of Plant Genetics and Crop Plant Research, has published a high-quality reference genome sequence for rye in Nature This is significant because, for the first time, the sequence includes the complete centromeres of all seven chromosome pairs. These regions are crucial for distributing genetic information correctly during cell division. While the study highlights rye as a source of useful genes for wheat breeding, it doesn't establish whether this genome will lead to improved wheat varieties in practice. In the realm of agriculture, researchers have developed a model of agrivoltaic systems, where solar panels and crops share the same land. This model simulates how the panels can cool crops and reduce heat stress for workers. The model was checked against a limited set of real-world measurements, with leaf temperatures from one location and soil temperatures from another. However, actual results on working commercial farms have not yet been demonstrated. Now let's talk about a fascinating discovery in microbiology. Scientists at the European Molecular Biology Laboratory found that phages, which are viruses that infect bacteria, can use a single enzyme called T7 kinase to shut down several bacterial defense systems at once. This is important because phages are being studied as a way to kill bacteria that resist standard antibiotics. Despite this promising discovery, phage therapy still faces practical limits, including a narrow host range, the potential for bacteria to evolve resistance, and various manufacturing and regulatory hurdles. Lastly, there's some early-stage research on a new approach for treating osteoarthritis. Supported by the Research Foundation for the State University of New York, this work describes an injectable hydrogel that forms a lubricating depot inside a joint after a single minimally invasive injection. The hydrogel holds drug-loaded nanocarriers in place for several weeks, releasing medication gradually. Osteoarthritis is a major cause of ongoing pain and disability, and current joint injections include analgesics, corticosteroids, and viscosupplements. However, this approach has not yet been shown to work as a treatment in people. We appreciate you listening. Until next time, take care. That's it for today. That was 5 Things Going Right. Come back tomorrow for 5 more.